Citi Pharma Pakheim acquisition CCP approval clears way
Citi Pharma Pakheim acquisition CCP approval clears a full buy of Pakheim under a May share deal, with payment due by 31 December 2026 from operating cash.
The Competition Commission of Pakistan authorised Citi Pharma Limited to buy 100% of Pakheim International Pharma (Private) Limited.
The CCP order is dated 9 October 2026 (Case No. 1614/Merger-CCP/2026) under Section 31(1)(d)(i) of the Competition Act, 2010.
The deal follows a Share Purchase Agreement dated 6 May 2026 and still needs remaining legal and regulatory formalities.
Pakheim’s annual revenue is about Rs500 million; Citi Pharma aims to lift that to Rs5 billion in five years.
Payment is flexible until 31 December 2026 and is to be met from operational cash flows.